Nakagawa-Goto, Kyoko, Wu, Pei-Chi, Bastow, Kenneth F., Yang, Shuenn-Chen, Yu, Sung-Liang, Chen, Hsuan-Yu, Lin, Jau-Chen, Goto, Masuo, Morris-Natschke, Susan L., Yang, Pan-Chyr, and Lee, Kuo-Hsiung
Abstract: In our ongoing study of the desmosdumotin C (1) series, twelve new analogues, 21–32, mainly with structural modifications in ring-A, were prepared and evaluated for in vitro antiproliferative activity against several human tumor cell lines. Among them, the 4′-iodo-3,3,5-tripropyl-4-methoxy analogue (31) showed significant antiproliferative activity against multiple human tumor cell lines with ED50 values of 1.1–2.8μM. Elongation of the C-3 and C-5 carbon chains reduced activity relative to propyl substituted analogues; however, activity was still better than that of natural compound 1. Among analogues with various ether groups on C-4, compounds with methyl (2) and propyl (26) ethers inhibited cell growth of multiple tumor cells lines, while 28 with an isobutyl ether showed selective antiproliferative activity against lung cancer A549 cells (ED50 1.7μM). The gene expression profiles showed that 3 may modulate the spindle assembly checkpoint (SAC) and chromosome separation, and thus, arrest cells at the G2/M-phase. [Copyright &y& Elsevier]